Preeclampsia Diagnostics Market Size Projected to Reach $1.46 billion by 2034 | 3.44%

According to Straits Research, the global preeclampsia diagnostics market size was valued at $1.08 billion in 2025 and is projected to grow from $1.11 billion in 2026 to $1.46 billion by 2034, registering a CAGR of 3.44% during the forecast period 2026–2034.

Market Dynamics

The growth of the preeclampsia diagnostics market is driven by the increasing emphasis on early detection of hypertensive disorders during pregnancy through biomarker-based testing, the rising integration of automated immunoassay platforms in hospital laboratories, and supportive clinical guidelines promoting risk stratification and timely intervention. However, limited accessibility to advanced diagnostic infrastructure in low- and middle-income regions, coupled with the high cost of biomarker assays and lack of awareness among healthcare providers in rural settings, continues to restrain market expansion. On the other hand, growing research into multi-marker predictive panels, the emergence of non-invasive molecular testing, and expanding government initiatives to strengthen prenatal screening programs present significant opportunities for companies to innovate and improve the reach of accurate and affordable preeclampsia diagnostics worldwide.

Market Segments

1. By Product Type (2026-2034)
   1. Instrument
   2. Consumables
2. By Test (2026-2034)
   1. Blood Test
   2. Urine Test
3. By End-User (2026-2034)
   1. Hospitals
   2. Specialty Clinics
   3. Diagnostic Centers
   4. Others